MAP2K7 and melanoma: It is necessary to consider that: i) RAS mutants are less sensitive to the MEK inhibitors in comparison to the BRAF mutant melanomas [14]; ii) NRAS mutants exhibit paradoxical activation of the MAPK pathway upon the treatment with the BRAF inhibitors such as vemurafenib [21]; and iii) there is possibility of reactivation of the pathway trough the adjustment of feedback systems.